These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 29268078

  • 1. Longitudinal uncoupling of cerebral perfusion, glucose metabolism, and tau deposition in Alzheimer's disease.
    Leuzy A, Rodriguez-Vieitez E, Saint-Aubert L, Chiotis K, Almkvist O, Savitcheva I, Jonasson M, Lubberink M, Wall A, Antoni G, Nordberg A.
    Alzheimers Dement; 2018 May; 14(5):652-663. PubMed ID: 29268078
    [Abstract] [Full Text] [Related]

  • 2. Comparability of [18F]THK5317 and [11C]PIB blood flow proxy images with [18F]FDG positron emission tomography in Alzheimer's disease.
    Rodriguez-Vieitez E, Leuzy A, Chiotis K, Saint-Aubert L, Wall A, Nordberg A.
    J Cereb Blood Flow Metab; 2017 Feb; 37(2):740-749. PubMed ID: 27107028
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer's disease.
    Leuzy A, Cicognola C, Chiotis K, Saint-Aubert L, Lemoine L, Andreasen N, Zetterberg H, Ye K, Blennow K, Höglund K, Nordberg A.
    Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1152-1163. PubMed ID: 30610252
    [Abstract] [Full Text] [Related]

  • 7. Tracer-specific reference tissues selection improves detection of 18 F-FDG, 18 F-florbetapir, and 18 F-flortaucipir PET SUVR changes in Alzheimer's disease.
    Li Y, Ng YL, Paranjpe MD, Ge Q, Gu F, Li P, Yan S, Lu J, Wang X, Zhou Y, for the Alzheimer's Disease Neuroimaging Initiative.
    Hum Brain Mapp; 2022 May; 43(7):2121-2133. PubMed ID: 35165964
    [Abstract] [Full Text] [Related]

  • 8. Do Tau Deposition and Glucose Metabolism Dissociate in Alzheimer's Disease Trajectory?
    Nowell J, Raza S, Livingston NR, Sivanathan S, Gentleman S, Edison P.
    J Alzheimers Dis; 2024 May; 101(3):987-999. PubMed ID: 39302365
    [Abstract] [Full Text] [Related]

  • 9. Tau positron emission tomography using [18F]THK5351 and cerebral glucose hypometabolism in Alzheimer's disease.
    Kang JM, Lee SY, Seo S, Jeong HJ, Woo SH, Lee H, Lee YB, Yeon BK, Shin DH, Park KH, Kang H, Okamura N, Furumoto S, Yanai K, Villemagne VL, Seong JK, Na DL, Ido T, Cho J, Lee KM, Noh Y.
    Neurobiol Aging; 2017 Nov; 59():210-219. PubMed ID: 28890300
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [18F]THK5317 imaging as a tool for predicting prospective cognitive decline in Alzheimer's disease.
    Chiotis K, Savitcheva I, Poulakis K, Saint-Aubert L, Wall A, Antoni G, Nordberg A.
    Mol Psychiatry; 2021 Oct; 26(10):5875-5887. PubMed ID: 32616831
    [Abstract] [Full Text] [Related]

  • 14. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ, Devous MD, Navitsky M, Lu M, Salloway S, Schaerf FW, Jennings D, Arora AK, McGeehan A, Lim NC, Xiong H, Joshi AD, Siderowf A, Mintun MA, 18F-AV-1451-A05 investigators.
    Brain; 2017 Mar 01; 140(3):748-763. PubMed ID: 28077397
    [Abstract] [Full Text] [Related]

  • 15. A cross-sectional comparison of brain glucose and ketone metabolism in cognitively healthy older adults, mild cognitive impairment and early Alzheimer's disease.
    Croteau E, Castellano CA, Fortier M, Bocti C, Fulop T, Paquet N, Cunnane SC.
    Exp Gerontol; 2018 Jul 01; 107():18-26. PubMed ID: 28709938
    [Abstract] [Full Text] [Related]

  • 16. Mitochondrial complex I abnormalities underlie neurodegeneration and cognitive decline in Alzheimer's disease.
    Terada T, Therriault J, Kang MS, Savard M, Pascoal TA, Lussier F, Tissot C, Wang YT, Benedet A, Poltronetti NM, Ottoy J, Arias JF, Bezgin G, Matsudaira T, Bunai T, Obi T, Tsukada H, Ouchi Y, Rosa-Neto P.
    Eur J Neurol; 2022 May 01; 29(5):1324-1334. PubMed ID: 35007366
    [Abstract] [Full Text] [Related]

  • 17. What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?
    Andriuta D, Moullart V, Schraen S, Devendeville A, Meyer ME, Godefroy O, Alzheimer’s Disease Neuroimaging.
    J Alzheimers Dis; 2016 May 01; 51(3):793-800. PubMed ID: 26923012
    [Abstract] [Full Text] [Related]

  • 18. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
    Iaccarino L, Chiotis K, Alongi P, Almkvist O, Wall A, Cerami C, Bettinardi V, Gianolli L, Nordberg A, Perani D.
    J Alzheimers Dis; 2017 May 01; 59(2):603-614. PubMed ID: 28671117
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.